Correction: Quinn et al. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. Vaccines 2023, 11, 175
Text Correction
- In Abstract, the text: “with a 1.5-log reduction in colonisation of the colon and caecum at 7 days relative to the adjuvant only (p = 0.0280)” should be replaced with “with a 1.25-log reduction in colonisation of the colon and caecum at 7 days relative to the adjuvant only (p = 0.0280)”.
- In Section 3.6, Paragraph 2, the text: “A 1.5-fold reduction in gastrointestinal colonisation (caecum and colon tissues combined, p = 0.0280)” should be replaced with “A 18-fold reduction in gastrointestinal colonisation (caecum and colon tissues combined, p = 0.0280)”.
- In Section 4, Paragraph 3, the text: “The mixed Th1/Th2 response stimulated by GlnH/SAS correlated with a log 1.5-fold reduction in NCTC12900Nalr CFU in the GI tracts of mice 7 d.p.i (p = 0.0280)” should be replaced with “The mixed Th1/Th2 response stimulated by GlnH/SAS correlated with a log 18-fold reduction in NCTC12900Nalr CFU in the GI tracts of mice 7 d.p.i (p = 0.0280)”.“Overall, GlnH in combination with SAS reduced the level of O157 colonisation by 1.5 log relative to that of the GI tracts of mice treated with adjuvant only” should be replaced with “Overall, GlnH in combination with SAS reduced the level of O157 colonisation by 1.25 log relative to that of the GI tracts of mice treated with adjuvant only”.
Reference
- Quinn, C.; Tomás-Cortázar, J.; Ofioritse, O.; Cosgrave, J.; Purcell, C.; McAloon, C.; Frost, S.; McClean, S. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. Vaccines 2023, 11, 175. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Quinn, C.; Tomás-Cortázar, J.; Ofioritse, O.; Cosgrave, J.; Purcell, C.; McAloon, C.; Frost, S.; McClean, S. Correction: Quinn et al. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. Vaccines 2023, 11, 175. Vaccines 2023, 11, 1414. https://doi.org/10.3390/vaccines11091414
Quinn C, Tomás-Cortázar J, Ofioritse O, Cosgrave J, Purcell C, McAloon C, Frost S, McClean S. Correction: Quinn et al. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. Vaccines 2023, 11, 175. Vaccines. 2023; 11(9):1414. https://doi.org/10.3390/vaccines11091414
Chicago/Turabian StyleQuinn, Conor, Julen Tomás-Cortázar, Oritsejolomi Ofioritse, Joanne Cosgrave, Claire Purcell, Catherine McAloon, Susanna Frost, and Siobhán McClean. 2023. "Correction: Quinn et al. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. Vaccines 2023, 11, 175" Vaccines 11, no. 9: 1414. https://doi.org/10.3390/vaccines11091414
APA StyleQuinn, C., Tomás-Cortázar, J., Ofioritse, O., Cosgrave, J., Purcell, C., McAloon, C., Frost, S., & McClean, S. (2023). Correction: Quinn et al. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. Vaccines 2023, 11, 175. Vaccines, 11(9), 1414. https://doi.org/10.3390/vaccines11091414